Rodger A. Liddle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rodger A. Liddle has a total of 303 co-authors. Here are the top co-authors by number of shared publications:
Rafiq A. Shahid
Department of Pathology, Brown University, Providence, Rhode Island
12 shared publications- Sandip Madhusudan Swain
Department of Medicine, Duke University, Durham, North Carolina, USA
10 shared publications Steven R. Vigna
Department of Medicine, Duke University Medical Center, Durham, North Carolina
8 shared publications- Rashmi Chandra
Department of Medicine
7 shared publications - Rafiq A. Shahid
Department of Medicine, Duke University Medical Center, Durham, North Carolina
6 shared publications Joelle M.-J. Romac
Department of Medicine, Duke University, Durham, North Carolina
5 shared publications
Latest Publications
- 28 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1369-1377
Incidence and Predictors of Acute Pancreatitis in Patients With Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS): A Multicenter Retrospective Study
- 28 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1369-1377
Incidence and Predictors of Acute Pancreatitis in Patients With Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS): A Multicenter Retrospective Study
- Top Cited PapersOpen Access
- 2 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (1)
Mechanisms and clinical implications of gut-brain interactions
Connections between the digestive system and the brain have been postulated for over 2000 years. Despite this, only recently have specific mechanisms of gut-brain interaction been identified. Due in large part to increased interest in the microbiome, the wide use of incretin-based therapies (i.e., glucagon-like peptide 1 [GLP-1] receptor agonists), technological advancements, increased understanding of neuroimmunology, and the identification of a direct enteroendocrine cell–neural circuit, research in the past 10 years has made it abundantly clear that the gut-brain connection plays a role both in clinical disease as well as the actions of therapeutics. In this Review, we describe mechanisms by which the gut and brain communicate and highlight human and animal studies that implicate changes in gut-brain communication in disease states in gastroenterology, neurology, psychiatry, and endocrinology. Furthermore, we define how GLP-1 receptor agonists for obesity and guanylyl cyclase C agonists for irritable bowel syndrome leverage gut-brain mechanisms to improve patient outcomes. This Review illustrates the critical nature of gut-brain communication in human disease and the potential to target gut-brain pathways for therapeutic benefit.
- 2 January 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (1)
Top Cited PapersOpen AccessMechanisms and clinical implications of gut-brain interactions
Connections between the digestive system and the brain have been postulated for over 2000 years. Despite this, only recently have specific mechanisms of gut-brain interaction been identified. Due in large part to increased interest in the microbiome, the wide use of incretin-based therapies (i.e., glucagon-like peptide 1 [GLP-1] receptor agonists), technological advancements, increased understanding of neuroimmunology, and the identification of a direct enteroendocrine cell–neural circuit, research in the past 10 years has made it abundantly clear that the gut-brain connection plays a role both in clinical disease as well as the actions of therapeutics. In this Review, we describe mechanisms by which the gut and brain communicate and highlight human and animal studies that implicate changes in gut-brain communication in disease states in gastroenterology, neurology, psychiatry, and endocrinology. Furthermore, we define how GLP-1 receptor agonists for obesity and guanylyl cyclase C agonists for irritable bowel syndrome leverage gut-brain mechanisms to improve patient outcomes. This Review illustrates the critical nature of gut-brain communication in human disease and the potential to target gut-brain pathways for therapeutic benefit.
- Open Access
- 16 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Loss of TRPV4 reduces pancreatic cancer growth and metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a rapidly metastasizing cancer characterized by a dense desmoplastic stroma composed of extracellular matrix (ECM) proteins, which complicates treatment. Upon stimulation, pancreatic stellate cells (PSCs) differentiated into cancer-associated fibroblasts (CAFs) that are the source of ECM and cytokines in PDAC. We previously reported that mechanical stress activates PSCs and induces fibrosis through mechanical ion channel PIEZO1-mediated TRPV4 channel activation, but its role in PDAC remains unclear. Here we report that pathological activation of PIEZO1 differentiated human PSCs into an inflammatory CAF phenotype that expresses chemoresistance and cancer stemness markers CD10 and GPR77. In an orthotopic PDAC model, TRPV4-KO mice exhibited a significant reduction in tumor size, circulating inflammatory cytokines, tissue inhibitor of metalloproteinases-1 (TIMP1), and premetastatic niche markers, serum amyloid A (SAA) proteins. A similar trend was observed in mice lacking functional PIEZO1 in PSCs. The livers of TRPV4-KO mice exhibited fewer cancer cell microlesions, lacked macrotumors, produced lower levels of inflammatory protein S100A8, and developed fewer inflammatory cell clusters. In orthotopic and genetically engineered models of PDAC, these mice also had improved survival, suggesting that blocking TRPV4 channels may be a promising therapeutic target for PDAC.
- 16 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (23)
Open AccessLoss of TRPV4 reduces pancreatic cancer growth and metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a rapidly metastasizing cancer characterized by a dense desmoplastic stroma composed of extracellular matrix (ECM) proteins, which complicates treatment. Upon stimulation, pancreatic stellate cells (PSCs) differentiated into cancer-associated fibroblasts (CAFs) that are the source of ECM and cytokines in PDAC. We previously reported that mechanical stress activates PSCs and induces fibrosis through mechanical ion channel PIEZO1-mediated TRPV4 channel activation, but its role in PDAC remains unclear. Here we report that pathological activation of PIEZO1 differentiated human PSCs into an inflammatory CAF phenotype that expresses chemoresistance and cancer stemness markers CD10 and GPR77. In an orthotopic PDAC model, TRPV4-KO mice exhibited a significant reduction in tumor size, circulating inflammatory cytokines, tissue inhibitor of metalloproteinases-1 (TIMP1), and premetastatic niche markers, serum amyloid A (SAA) proteins. A similar trend was observed in mice lacking functional PIEZO1 in PSCs. The livers of TRPV4-KO mice exhibited fewer cancer cell microlesions, lacked macrotumors, produced lower levels of inflammatory protein S100A8, and developed fewer inflammatory cell clusters. In orthotopic and genetically engineered models of PDAC, these mice also had improved survival, suggesting that blocking TRPV4 channels may be a promising therapeutic target for PDAC.
- Open Access
- 26 August 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (16) , e70983
Phosphate Improves Mitochondrial Function and Reduces Pancreatitis in Hypertriglyceridemia
Hypertriglyceridemia‐associated pancreatitis (HTGP) accounts for 9% to 10% of acute pancreatitis; however, the exact cause and associated factors advancing HTGP are unclear. Clinical studies have revealed that hypophosphatemia is a common factor in many patients with pancreatitis. Phosphate depletion occurs in metabolic disorders and can lead to dyslipidemia. To determine if phosphate status is critical in HTGP, we used an APOC3 transgenic mouse model of hypertriglyceridemia. We found that hypertriglyceridemic mice exhibit mild pancreatic injury with elevated intra‐acinar nonendoplasmic reticulum (non‐ER) organelle calcium levels, decreased mitochondrial function, and increased levels of pancreatic tissue myeloperoxidase and proinflammatory cytokines (TNF‐α, IL‐6, and IL‐1β) compared to mice with normal serum triglycerides. Phosphate supplementation normalized the non‐ER stored calcium levels, restored mitochondrial function, and attenuated fatty acid‐induced sustained intracellular calcium elevation in acini, protecting the pancreas from hypertriglyceridemia‐induced injury by reducing inflammation. Furthermore, phosphate supplementation reduced the severity of caerulein‐induced pancreatic injury in mice on a low‐phosphate diet under hypertriglyceridemic conditions. This study highlights an important role for phosphate in protecting the pancreas during hypertriglyceridemia by reversing the dysregulated calcium homeostasis in non‐ER organelles, restoring mitochondrial function in acini, and reducing the severity of hypertriglyceridemia‐associated pancreatitis.
- 26 August 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (16) , e70983
Open AccessPhosphate Improves Mitochondrial Function and Reduces Pancreatitis in Hypertriglyceridemia
Hypertriglyceridemia‐associated pancreatitis (HTGP) accounts for 9% to 10% of acute pancreatitis; however, the exact cause and associated factors advancing HTGP are unclear. Clinical studies have revealed that hypophosphatemia is a common factor in many patients with pancreatitis. Phosphate depletion occurs in metabolic disorders and can lead to dyslipidemia. To determine if phosphate status is critical in HTGP, we used an APOC3 transgenic mouse model of hypertriglyceridemia. We found that hypertriglyceridemic mice exhibit mild pancreatic injury with elevated intra‐acinar nonendoplasmic reticulum (non‐ER) organelle calcium levels, decreased mitochondrial function, and increased levels of pancreatic tissue myeloperoxidase and proinflammatory cytokines (TNF‐α, IL‐6, and IL‐1β) compared to mice with normal serum triglycerides. Phosphate supplementation normalized the non‐ER stored calcium levels, restored mitochondrial function, and attenuated fatty acid‐induced sustained intracellular calcium elevation in acini, protecting the pancreas from hypertriglyceridemia‐induced injury by reducing inflammation. Furthermore, phosphate supplementation reduced the severity of caerulein‐induced pancreatic injury in mice on a low‐phosphate diet under hypertriglyceridemic conditions. This study highlights an important role for phosphate in protecting the pancreas during hypertriglyceridemia by reversing the dysregulated calcium homeostasis in non‐ER organelles, restoring mitochondrial function in acini, and reducing the severity of hypertriglyceridemia‐associated pancreatitis.
- Open Access
- 30 January 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-18
Lewy body diseases and the gut
Gastrointestinal (GI) involvement in Lewy body diseases (LBDs) has been observed since the initial descriptions of patients by James Parkinson. Recent experimental and human observational studies raise the possibility that pathogenic alpha-synuclein (⍺-syn) might develop in the GI tract and subsequently spread to susceptible brain regions. The cellular and mechanistic origins of ⍺-syn propagation in disease are under intense investigation. Experimental LBD models have implicated important contributions from the intrinsic gut microbiome, the intestinal immune system, and environmental toxicants, acting as triggers and modifiers to GI pathologies. Here, we review the primary clinical observations that link GI dysfunctions to LBDs. We first provide an overview of GI anatomy and the cellular repertoire relevant for disease, with a focus on luminal-sensing cells of the intestinal epithelium including enteroendocrine cells that express ⍺-syn and make direct contact with nerves. We describe interactions within the GI tract with resident microbes and exogenous toxicants, and how these may directly contribute to ⍺-syn pathology along with related metabolic and immunological responses. Finally, critical knowledge gaps in the field are highlighted, focusing on pivotal questions that remain some 200 years after the first descriptions of GI tract dysfunction in LBDs. We predict that a better understanding of how pathophysiologies in the gut influence disease risk and progression will accelerate discoveries that will lead to a deeper overall mechanistic understanding of disease and potential therapeutic strategies targeting the gut-brain axis to delay, arrest, or prevent disease progression.
- 30 January 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-18
Open AccessLewy body diseases and the gut
Gastrointestinal (GI) involvement in Lewy body diseases (LBDs) has been observed since the initial descriptions of patients by James Parkinson. Recent experimental and human observational studies raise the possibility that pathogenic alpha-synuclein (⍺-syn) might develop in the GI tract and subsequently spread to susceptible brain regions. The cellular and mechanistic origins of ⍺-syn propagation in disease are under intense investigation. Experimental LBD models have implicated important contributions from the intrinsic gut microbiome, the intestinal immune system, and environmental toxicants, acting as triggers and modifiers to GI pathologies. Here, we review the primary clinical observations that link GI dysfunctions to LBDs. We first provide an overview of GI anatomy and the cellular repertoire relevant for disease, with a focus on luminal-sensing cells of the intestinal epithelium including enteroendocrine cells that express ⍺-syn and make direct contact with nerves. We describe interactions within the GI tract with resident microbes and exogenous toxicants, and how these may directly contribute to ⍺-syn pathology along with related metabolic and immunological responses. Finally, critical knowledge gaps in the field are highlighted, focusing on pivotal questions that remain some 200 years after the first descriptions of GI tract dysfunction in LBDs. We predict that a better understanding of how pathophysiologies in the gut influence disease risk and progression will accelerate discoveries that will lead to a deeper overall mechanistic understanding of disease and potential therapeutic strategies targeting the gut-brain axis to delay, arrest, or prevent disease progression.
- 4 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (2) , 323
The John Williams autobiography: “The Pancreas and Me"
- 4 January 2024
- Published by Elsevier in Pancreatology
- Vol. 24 (2) , 323
The John Williams autobiography: “The Pancreas and Me"
- Open Access
- 8 December 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (23)
Gut mucosal cells transfer α-synuclein to the vagus nerve
Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson’s disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.
- 8 December 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (23)
Open AccessGut mucosal cells transfer α-synuclein to the vagus nerve
Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson’s disease. Although past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut-to-brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of intestinal mucosa express α-synuclein. Here, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from epithelial cells in organoids to cocultured nodose neurons devoid of α-synuclein. In mice expressing human α-synuclein, but no mouse α-synuclein, α-synuclein fibril-templating activity emerged in α-synuclein–seeded fibril aggregation assays in intestine, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfered to the vagus nerve and dorsal motor nucleus. Subdiaphragmatic vagotomy prior to induction of α-synuclein expression in intestinal epithelial cells effectively protected the hindbrain from emergence of α-synuclein fibril-templating activity. Overall, these findings highlight a potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.
- Open Access
- 15 November 2023
- Published by Wolters Kluwer Health in Pancreas
- Vol. 53 (1) , e3-e8
Hypophosphatemia as a Predictor of Clinical Outcomes in Acute Pancreatitis
Objective: Phosphate is crucial for cellular repair after injury and may be important in recovery following acute pancreatitis (AP). This study aimed to evaluate the association between hypophosphatemia and severity of AP. Methods: Patients admitted with AP between 2014–2018 were identified and their records were retrospectively reviewed. Pancreatitis severity was defined using the modified Atlanta Criteria. Hypophosphatemia was defined as phosphate P < 0.001; one day: 47.4% vs. 23.9%, P = 0.004; two days: 42.9% vs. 24.5%, P = 0.01). Patients with hypophosphatemia within one day were also more likely to have ICU admission (P < 0.001) and longer length of stay (P < 0.001). Conclusions: Early hypophosphatemia during an admission for AP was associated with increased AP severity, ICU admission, and longer length of stay.
- 15 November 2023
- Published by Wolters Kluwer Health in Pancreas
- Vol. 53 (1) , e3-e8
Open AccessHypophosphatemia as a Predictor of Clinical Outcomes in Acute Pancreatitis
Objective: Phosphate is crucial for cellular repair after injury and may be important in recovery following acute pancreatitis (AP). This study aimed to evaluate the association between hypophosphatemia and severity of AP. Methods: Patients admitted with AP between 2014–2018 were identified and their records were retrospectively reviewed. Pancreatitis severity was defined using the modified Atlanta Criteria. Hypophosphatemia was defined as phosphate P < 0.001; one day: 47.4% vs. 23.9%, P = 0.004; two days: 42.9% vs. 24.5%, P = 0.01). Patients with hypophosphatemia within one day were also more likely to have ICU admission (P < 0.001) and longer length of stay (P < 0.001). Conclusions: Early hypophosphatemia during an admission for AP was associated with increased AP severity, ICU admission, and longer length of stay.
- Open Access
- 2 October 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (19)
Mechanosensing Piezo channels in gastrointestinal disorders
All cells in the body are exposed to physical force in the form of tension, compression, gravity, shear stress, or pressure. Cells convert these mechanical cues into intracellular biochemical signals; this process is an inherent property of all cells and is essential for numerous cellular functions. A cell’s ability to respond to force largely depends on the array of mechanical ion channels expressed on the cell surface. Altered mechanosensing impairs conscious senses, such as touch and hearing, and unconscious senses, like blood pressure regulation and gastrointestinal (GI) activity. The GI tract’s ability to sense pressure changes and mechanical force is essential for regulating motility, but it also underlies pain originating in the GI tract. Recent identification of the mechanically activated ion channels Piezo1 and Piezo2 in the gut and the effects of abnormal ion channel regulation on cellular function indicate that these channels may play a pathogenic role in disease. Here, we discuss our current understanding of mechanically activated Piezo channels in the pathogenesis of pancreatic and GI diseases, including pancreatitis, diabetes mellitus, irritable bowel syndrome, GI tumors, and inflammatory bowel disease. We also describe how Piezo channels could be important targets for treating GI diseases.
- 2 October 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (19)
Open AccessMechanosensing Piezo channels in gastrointestinal disorders
All cells in the body are exposed to physical force in the form of tension, compression, gravity, shear stress, or pressure. Cells convert these mechanical cues into intracellular biochemical signals; this process is an inherent property of all cells and is essential for numerous cellular functions. A cell’s ability to respond to force largely depends on the array of mechanical ion channels expressed on the cell surface. Altered mechanosensing impairs conscious senses, such as touch and hearing, and unconscious senses, like blood pressure regulation and gastrointestinal (GI) activity. The GI tract’s ability to sense pressure changes and mechanical force is essential for regulating motility, but it also underlies pain originating in the GI tract. Recent identification of the mechanically activated ion channels Piezo1 and Piezo2 in the gut and the effects of abnormal ion channel regulation on cellular function indicate that these channels may play a pathogenic role in disease. Here, we discuss our current understanding of mechanically activated Piezo channels in the pathogenesis of pancreatic and GI diseases, including pancreatitis, diabetes mellitus, irritable bowel syndrome, GI tumors, and inflammatory bowel disease. We also describe how Piezo channels could be important targets for treating GI diseases.
- Open Access
Gut mucosal cells transfer α-synuclein to the vagus nerve
Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson’s disease (PD). While past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut to brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of the gut mucosa express α-synuclein. In this study, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from gut epithelial cells in organoids co-cultured with vagal nodose neurons that are otherwise devoid of α-synuclein expression. In intact mice that express pathological human α-synuclein, but no mouse α-synuclein, α-synuclein fibril templating activity emerges in α-synuclein seeded fibril aggregation assays in tissues from the gut, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfers to the vagus nerve and to the dorsal motor nucleus. Subdiaphragmatic vagotomy prior to the induction of α-synuclein expression in the gut epithelial cells effectively protects the hindbrain from the emergence of α-synuclein fibril templating activity. Overall, these findings highlight a novel potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.
Open AccessGut mucosal cells transfer α-synuclein to the vagus nerve
Epidemiological and histopathological findings have raised the possibility that misfolded α-synuclein protein might spread from the gut to the brain and increase the risk of Parkinson’s disease (PD). While past experimental studies in mouse models have relied on gut injections of exogenous recombinant α-synuclein fibrils to study gut to brain α-synuclein transfer, the possible origins of misfolded α-synuclein within the gut have remained elusive. We recently demonstrated that sensory cells of the gut mucosa express α-synuclein. In this study, we employed mouse intestinal organoids expressing human α-synuclein to observe the transfer of α-synuclein protein from gut epithelial cells in organoids co-cultured with vagal nodose neurons that are otherwise devoid of α-synuclein expression. In intact mice that express pathological human α-synuclein, but no mouse α-synuclein, α-synuclein fibril templating activity emerges in α-synuclein seeded fibril aggregation assays in tissues from the gut, vagus nerve, and dorsal motor nucleus. In newly engineered transgenic mice that restrict pathological human α-synuclein expression to intestinal epithelial cells, α-synuclein fibril-templating activity transfers to the vagus nerve and to the dorsal motor nucleus. Subdiaphragmatic vagotomy prior to the induction of α-synuclein expression in the gut epithelial cells effectively protects the hindbrain from the emergence of α-synuclein fibril templating activity. Overall, these findings highlight a novel potential non-neuronal source of fibrillar α-synuclein protein that might arise in gut mucosal cells.